571 related articles for article (PubMed ID: 24698965)
21. HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.
Perron M; Wen HY; Hanna MG; Brogi E; Ross DS
Arch Pathol Lab Med; 2021 Aug; 145(8):979-987. PubMed ID: 33212478
[TBL] [Abstract][Full Text] [Related]
22. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
23. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
[TBL] [Abstract][Full Text] [Related]
24. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
25. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Gong Y; Sweet W; Duh YJ; Greenfield L; Tarco E; Trivedi S; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Aug; 132(2):228-36. PubMed ID: 19605817
[TBL] [Abstract][Full Text] [Related]
26. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
27. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
28. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
Chao WR; Lee MY; Lin WL; Koo CL; Sheu GT; Han CP
Am J Surg Pathol; 2014 Sep; 38(9):1227-34. PubMed ID: 25133707
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
30. Genetic heterogeneity in HER2 testing may influence therapy eligibility.
Bernasconi B; Chiaravalli AM; Finzi G; Milani K; Tibiletti MG
Breast Cancer Res Treat; 2012 May; 133(1):161-8. PubMed ID: 21901388
[TBL] [Abstract][Full Text] [Related]
31. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
32. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
33. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
Chen PC; Yu HJ; Chang YH; Pan CC
J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
35. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.
Stewart RL; Caron JE; Gulbahce EH; Factor RE; Geiersbach KB; Downs-Kelly E
Mod Pathol; 2017 Nov; 30(11):1561-1566. PubMed ID: 28752841
[TBL] [Abstract][Full Text] [Related]
36. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
37. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
38. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
39. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
40. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
